Document is current
Any future updates will be listed below
-
Authors
Garrido, Victoria https://orcid.org/0000-0002-2497-7188
Piñero‐Lambea, Carlos https://orcid.org/0000-0002-5263-3702
Rodriguez‐Arce, Irene https://orcid.org/0000-0003-4752-3725
Paetzold, Bernhard https://orcid.org/0000-0003-3882-9036
Ferrar, Tony https://orcid.org/0000-0002-4606-1613
Weber, Marc https://orcid.org/0000-0001-7920-5655
Garcia‐Ramallo, Eva
Gallo, Carolina https://orcid.org/0000-0003-3811-1841
Collantes, María https://orcid.org/0000-0003-1162-1470
Peñuelas, Iván https://orcid.org/0000-0001-8008-976X
Serrano, Luis https://orcid.org/0000-0002-5276-1392
Grilló, María‐Jesús https://orcid.org/0000-0002-1819-0186
Lluch‐Senar, María https://orcid.org/0000-0001-7568-4353
-
Funding
Funding for this research was provided by:
H2020 European Research Council (634942)
- License Information
-
More Information
Article History
Received: 1 December 2020
Revised: 14 September 2021
Accepted: 15 September 2021
First Online: 6 October 2021
Conflict of interest
: The work described here was done before the creation of the start‐up Pulmobiotics. In any case, we would like to state that Carlos Piñero‐Lambea and Maria Lluch‐Senar are now working in Pulmobiotics Company and Luis Serrano and Maria Lluch‐Senar are co‐founders of the company. This company is interested in the development of M. pneumoniae as a vector to treat human lung diseases. There are three patents protecting the results shown in the current work (EP 16706622.4; EP20382208.5 and EP20382288).
